Physician profile
Mikhail Kotlov
NPI 1891840872
$6,183.30
in general payments reported to CMS, 2019-2025
31 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $1,441 · 2021: $362 · 2022: $762 · 2023: $1,183 · 2024: $1,322 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,030 · Education: $21.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.08 |
| Education | $21.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,203.50 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $1,021.85 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $616.49 | 2019-2023 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $505.45 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $460.22 | 2019-2025 | |
| Amgen INC. | $401.08 | 2020-2025 | Tavneos, Parsabiv, Aranesp |
| Novartis Pharmaceuticals Corporation | $301.29 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $253.60 | 2021-2024 | |
| Fresenius USA Marketing, INC. | $190.95 | 2023-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $188.96 | 2023-2024 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $167.44 | 2023-2024 | Lupkynis |
| Baxter Healthcare | $140.82 | 2024 | Renal - Pd |
| Mozarc Medical US LLC | $119.05 | 2024 | Argyle |
| Glaxosmithkline, LLC. | $110.77 | 2022-2024 | Benlysta, Jesduvroq |
| Novo Nordisk INC | $67.97 | 2024-2025 | Wegovy, Rivfloza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $51.76 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $48.65 | 2022-2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.61 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $46.66 | 2022-2023 | Ultomiris |
| Corcept Therapeutics | $37.69 | 2025 | Korlym |
| Lilly USA, LLC | $32.19 | 2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $23.92 | 2025 | Empaveli |
| Genentech USA, INC. | $19.57 | 2022 | |
| Opko Pharmaceuticals, LLC | $18.18 | 2023 | Rayaldee |
| Genzyme Corporation | $17.68 | 2024 | |
| Mallinckrodt Hospital Products INC. | $16.76 | 2023 | Acthar |
| Scpharmaceuticals INC. | $16.33 | 2025 | |
| Aimmune Therapeutics, INC. | $15.73 | 2024 | |
| Strongbridge US INC. | $15.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.50 | 2019 | |
| Endo Pharmaceuticals INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Kotlov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.